Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Colleen Watt"'
Autor:
Michael J. Morris, Glenn Heller, David W. Hillman, Olivia Bobek, Charles Ryan, Emmanuel S. Antonarakis, Alan H. Bryce, Olwen Hahn, Himisha Beltran, Andrew J. Armstrong, Lawrence Schwartz, Lionel D. Lewis, Jan H. Beumer, Brooke Langevin, Eric C. McGary, Paul T. Mehan, Amir Goldkorn, Bruce J. Roth, Han Xiao, Colleen Watt, Mary-Ellen Taplin, Susan Halabi, Eric J. Small
Publikováno v:
Journal of Clinical Oncology.
PURPOSE Enzalutamide and abiraterone both target androgen receptor signaling but via different mechanisms. The mechanism of action of one drug may counteract the resistance pathways of the other. We sought to determine whether the addition of abirate
Autor:
Steven E. Schild, Xiaofei Wang, Christine M. Bestvina, Terence Williams, Greg Masters, Anurag K. Singh, Thomas E. Stinchcombe, Joseph K. Salama, Steven Wolf, Tyler Zemla, Narjust Duma, Stephen G. Chun, Arya Amini, David Kozono, Colleen Watt
Publikováno v:
Clin Lung Cancer
INTRODUCTION: Treatment of advanced stage non-small cell lung cancer (NSCLC) has changed dramatically due to immunotherapy. However, patients without Programmed Death-Ligand 1 (PD-L1) protein expression often benefit less from immunotherapy. This tri
Autor:
Arpit Rao, Glenn Heller, Charles J. Ryan, David James VanderWeele, Lionel D Lewis, Alan Tan, Colleen Watt, Ronald C. Chen, Manish Kohli, Pedro C. Barata, Benjamin Adam Gartrell, Robert Grubb, Amylou C. Dueck, Yujia Wen, Michael J. Morris
Publikováno v:
Journal of Clinical Oncology. 40:TPS5107-TPS5107
TPS5107 Background: Despite a growing number of treatment options for first line mCRPC, approximately 40% of patients (pts) have radiographic progression within the first year. Androgen receptor (AR) signaling inhibition increases genomic instability
Autor:
Arpit Rao, Glenn Heller, Charles J. Ryan, David James VanderWeele, Lionel D Lewis, Alan Tan, Colleen Watt, Ronald C. Chen, Manish Kohli, Pedro C. Barata, Benjamin Adam Gartrell, Robert Grubb, Amylou C. Dueck, Yujia Wen, Michael J. Morris
Publikováno v:
Journal of Clinical Oncology. 40:TPS194-TPS194
TPS194 Background: Despite a growing number of treatment options for first line mCRPC, approximately 40% of patients (pts) have radiographic progression within the first year. Androgen receptor (AR) signaling inhibition increases genomic instability
Autor:
Eric J. Small, Martin E. Gleave, Mary-Ellen Taplin, Saby George, Susan Halabi, Christopher P. Evans, David W. Hillman, Himisha Beltran, J. Kellogg Parsons, Olwen Hahn, James L. Mohler, Russell Z. Szmulewitz, Glenn Heller, Michael J. Morris, James A. Eastham, Martin G. Sanda, Jonathan A. Coleman, J. Paul Monk, Colleen Watt, Steven K. Clinton
Publikováno v:
J Clin Oncol
PURPOSERadical prostatectomy (RP) alone is often inadequate in curing men with clinically localized, high-risk prostate cancer (PC). We hypothesized that chemohormonal therapy (CHT) with androgen-deprivation therapy plus docetaxel before RP would imp
Autor:
James A. Eastham, Susan Halabi, Christopher P. Evans, James L. Mohler, Martin E. Gleave, Russell Z. Szmulewitz, Himisha Beltran, Jonathan A. Coleman, Steven K. Clinton, J. Paul Monk, Olwen Hahn, Colleen Watt, Mary-Ellen Taplin, Glenn Heller, Michael J. Morris, Eric J. Small, David W. Hillman
Publikováno v:
Journal of Urology. 201
INTRODUCTION AND OBJECTIVES:Radical prostatectomy (RP) is a mainstay of treatment for men with clinically localized, high risk prostate cancer (CLHRPC). We assessed whether chemohormonal therapy wi...
Autor:
Atish D. Choudhury, Ulka N. Vaishampayan, Hamid Emamekhoo, Tyler Zemla, Colleen Watt, Ronald C. Chen, Toni K. Choueiri, Yujia Wen, Karla V. Ballman, Daniel J. George, Ardaman Shergill, Tian Zhang, Michael J. Morris
Publikováno v:
Journal of Clinical Oncology. 39:TPS366-TPS366
TPS366 Background: First-line treatment of mRCC has rapidly changed to include IPI-NIVO or CABO, with clinical benefit of each based on the Checkmate 214 and CABOSUN (A031203) trials. Combination immunotherapy with VEGF therapies has shown benefit ov
Autor:
Olwen Hahn, Charles J. Ryan, Robert L. Grubb, Colleen Watt, Lionel D. Lewis, David J. VanderWeele, Glenn Heller, Ronald C. Chen, Michael J. Morris, Arpit Rao, Himisha Beltran
Publikováno v:
Journal of Clinical Oncology. 39:TPS181-TPS181
TPS181 Background: Treatment with novel antiandrogens (NAA) and androgen deprivation therapy prolongs life in men with mCRPC but approximately 40% patients (pts) have radiographic progression within the first year. Inhibition of androgen receptor sig
Autor:
Walter M. Stadler, Karla V. Ballman, Thomas W. Flaig, Olwen Hahn, Jonathan E. Rosenberg, Susan Halabi, Robert Dreicer, Amir Mortazavi, Michael J. Morris, Colleen Watt, Preston D. Steen, Christopher Sweeney
Publikováno v:
Journal of Clinical Oncology. 37:4503-4503
4503 Background: The combination of gemcitabine (G) and cisplatin (C) is a standard therapy for metastatic urothelial carcinoma (mUC). Based on data that angiogenesis plays a role in UC growth and progression, a randomized placebo-controlled trial wa
Autor:
Colleen Watt, Bruce J. Roth, Andrew J. Armstrong, Eric J. Small, Charles J. Ryan, Olwen Hahn, Susan Halabi, Himisha Beltran, Amir Goldkorn, Michael J. Morris, David W. Hillman, Mary-Ellen Taplin, Paul Tracy Mehan, Glenn Heller, Han Xiao, Alan H. Bryce, Eric C. McGary
Publikováno v:
Journal of Clinical Oncology. 37:5008-5008
5008 Background: Androgen receptor (AR) signaling is an important growth mechanism in mCRPC, providing the rationale for treatment with AR axis inhibitors such as ENZ and AAP. Targeting AR with anti-androgens such as ENZ can result in compensatory au